Show simple item record

Advances in immunotherapy for MMR proficient colorectal cancer.

dc.contributor.authorLote, H
dc.contributor.authorStarling, N
dc.contributor.authorPihlak, R
dc.contributor.authorGerlinger, M
dc.coverage.spatialNetherlands
dc.date.accessioned2023-01-04T12:32:59Z
dc.date.available2023-01-04T12:32:59Z
dc.date.issued2022-12-01
dc.identifierARTN 102480
dc.identifierS0305-7372(22)00149-9
dc.identifier.citationCancer Treatment Reviews, 2022, 111 pp. 102480 -en_US
dc.identifier.issn0305-7372
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5632
dc.identifier.eissn1532-1967
dc.identifier.eissn1532-1967
dc.identifier.doi10.1016/j.ctrv.2022.102480
dc.description.abstractSurvival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect profile in various cancer types and multiple clinical trials have been conducted in MMRp mCRC. In this review we summarise emerging trial data which demonstrate promising immunotherapy combinations in MMRp mCRC. We outline barriers to success, evaluate emerging biomarkers and discuss potential strategies to increase the effectiveness of immunotherapy in MMRp mCRC.
dc.formatPrint-Electronic
dc.format.extent102480 -
dc.languageeng
dc.language.isoengen_US
dc.publisherELSEVIER SCI LTDen_US
dc.relation.ispartofCancer Treatment Reviews
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectHumans
dc.subjectDNA Mismatch Repair
dc.subjectColorectal Neoplasms
dc.subjectImmunotherapy
dc.titleAdvances in immunotherapy for MMR proficient colorectal cancer.en_US
dc.typeJournal Article
dcterms.dateAccepted2022-10-26
dc.date.updated2023-01-04T12:32:17Z
rioxxterms.versionVoRen_US
rioxxterms.versionofrecord10.1016/j.ctrv.2022.102480en_US
rioxxterms.licenseref.startdate2022-12-01
rioxxterms.typeJournal Article/Reviewen_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/36335756
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Translational Oncogenomics
pubs.organisational-group/ICR/ImmNet
pubs.publication-statusPublished
pubs.publisher-urlhttp://dx.doi.org/10.1016/j.ctrv.2022.102480
pubs.volume111
icr.researchteamTransl Oncogenomicsen_US
dc.contributor.icrauthorGerlinger, Marco
icr.provenanceDeposited by Mr Arek Surman on 2023-01-04. Deposit type is initial. No. of files: 1. Files: PIIS0305737222001499.pdf


Files in this item

Thumbnail
Name:
PIIS0305737222001499.pdf
Size:
1.855Mb
Format:
PDF
View/Open

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/